
Denali Therapeutics (DNLI) Stock Forecast & Price Target
Denali Therapeutics (DNLI) Analyst Ratings
Bulls say
Denali Therapeutics Inc is poised for growth with the imminent filing of its tivi biologics license application (BLA) and anticipated market share gains from 2026, bolstered by synergies from in-house manufacturing capabilities for its transport vehicles. Clinical data demonstrate substantial improvements in liver volume and cognitive function among participants, highlighting the effectiveness of its products, particularly DNL310, which is positioned to outperform existing therapies in the market. Financially, the company's operational expenditures are tracking below estimates, with a reasonable anticipated increase of 10-15% for fiscal year 2025, further indicating sound financial management amidst ongoing advancements in its development pipeline.
Bears say
Denali Therapeutics Inc. faces significant risks that contribute to a negative outlook on its stock, primarily due to potential delays or failures in the development and commercialization of its product candidates, which could severely impact business prospects and financial results. The discontinuation of the III dose cohort for Elaprase raises concerns about long-term durability in gene therapy approaches, potentially delaying revenue generation and negatively affecting forecasts. Furthermore, issues related to the deployment of existing monoclonal antibody treatments and the recent net loss reported by the company further underscore the uncertainty surrounding acceptable safety and efficacy endpoints in ongoing clinical trials, amplifying the risks associated with investment in the company.
This aggregate rating is based on analysts' research of Denali Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Denali Therapeutics (DNLI) Analyst Forecast & Price Prediction
Start investing in Denali Therapeutics (DNLI)
Order type
Buy in
Order amount
Est. shares
0 shares